Ascendis Pharma A (ASND) Operating Expenses (2014 - 2026)

Ascendis Pharma A has disclosed Operating Expenses across 13 years of filings, most recently posting -$239.2 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at -$239.2 million, down 21.16% year-over-year; the trailing twelve-month figure through Mar 2026 was -$357.2 million (down 65.46% YoY), and the FY2025 annual result was -$110.6 million, down 256.82% from the prior year.
• Operating Expenses came in at -$239.2 million for Q1 2026 at Ascendis Pharma A, down from -$110.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $203.2 million in Q2 2025 to a low of -$239.2 million in Q1 2026.
• The 5-year median for Operating Expenses is $146.6 million (2022), against an average of $26.3 million.
• Across the five-year window, Operating Expenses surged 48.9% in 2024 and slumped 256.82% in 2025, its largest moves.
• Ascendis Pharma A's Operating Expenses stood at -$97.4 million in 2022, then soared by 37.74% to -$60.6 million in 2023, then soared by 48.9% to -$31.0 million in 2024, then plunged by 256.82% to -$110.6 million in 2025, then plunged by 116.27% to -$239.2 million in 2026.
• The last three Operating Expenses figures came in at -$239.2 million (Q1 2026), -$110.6 million (Q4 2025), and -$210.8 million (Q3 2025), per Business Quant data.